*Clostridium difficile* infection is a growing public health threat^[@R3]^. Susceptibility to infection is associated with antibiotic use^[@R3]^, and fecal microbiota transplant (FMT), which restores microbiota complexity, can resolve recurrent infections^[@R4]^. However the microbiome-encoded genes and biosynthetic gene clusters^[@R5]^ critical for infection resistance remain largely undefined, limiting mechanistic understanding and development of microbiota-based therapies. We sought to identify, interrogate, and validate sources of microbiome-mediated *C. difficile* resistance. We first investigated the impact of antibiotics with diverse antimicrobial spectra on the intestinal microbiota and *C. difficile* susceptibility ([Extended Data Fig. 1a](#F1){ref-type="fig"}). Consistent with prior work from our group^[@R2]^, clindamycin administration resulted in long-lasting susceptibility to infection ([Fig. 1a](#F9){ref-type="fig"}). In contrast, ampicillin induced transient susceptibility ([Fig. 1c](#F9){ref-type="fig"}), while enrofloxacin did not increase susceptibility to *C. difficile* infection ([Fig. 1e](#F9){ref-type="fig"}). *C. difficile* toxin expression correlated significantly with *C. difficile* abundance in the intestine ([Extended Data Fig. 1b](#F1){ref-type="fig"}). The antibiotic regimens did not substantially alter bacterial density ([Extended Data Fig. 1c](#F1){ref-type="fig"}), but 16S rRNA gene amplicon sequencing revealed that the three antibiotics had distinct impacts on intestinal microbiota composition ([Fig. 1b, d, f](#F9){ref-type="fig"}).

We exploited this variance in intestinal bacterial composition and infection susceptibility to relate features of microbiota structure to *C.difficile* inhibition. Infection susceptibility correlated with decreased microbiota alpha diversity (i.e. diversity within individuals) ([Fig. 2a](#F10){ref-type="fig"}), consistent with previous studies^[@R6]^. Using weighted UniFrac^[@R7]^ distances to evaluate beta diversity (i.e. diversity between individuals), we found that although clindamycin and ampicillin administration induced distinct changes in microbiota structure, recovery of resistance corresponded with return to a common coordinate space shared by antibiotic-naïve animals ([Fig. 2b](#F10){ref-type="fig"}). However, these diversity metrics generally did not resolve the susceptibility status of animals harboring microbiota with low alpha diversity ([Fig. 2a](#F10){ref-type="fig"} (red box)) or at early timepoints post-antibiotic exposure ([Fig. 2b](#F10){ref-type="fig"}), suggesting that recovery of more precise microbiota features (e.g. individual species) contributed to infection resistance. We correlated resistance with individual bacterial species abundances, corresponding to operational taxonomic units (OTUs, ≥97% 16S sequence identity) ([Extended Data Fig. 1d](#F1){ref-type="fig"}), and identified 11 bacterial OTUs that correlated strongly with infection resistance ([Fig. 2c](#F10){ref-type="fig"}). These OTUs represent a small fraction of the microbiota membership (6%) and were comprised primarily by *Clostridium* cluster XIVa, including the OTU with the strongest resistance correlation, even among animals harboring low-alpha diversity microbiota, *Clostridium scindens* ([Figure 2c](#F10){ref-type="fig"}).

To relate intestinal bacterial species to *C. difficile* resistance in humans, we extended our study to a cohort of patients undergoing allogeneic hematopoeietic stem cell transplantation (allo-HSCT). The majority of these patients were diagnosed with a hematological malignancy and received chemotherapy and/or total body irradiation as well as antibiotics during transplantation ([Extended Data Table 1](#T1){ref-type="table"}), incurring reduced microbiota biodiversity associated with increased risk of bacterial blood stream infections^[@R8]^ and *C. difficile* infection^[@R9]^. Compared to controlled animal studies, temporal variation in antibiotic administration and sampling times among patients complicates analysis of relationships between microbiota composition and infection susceptibility. To address these challenges we employed a recently developed systems biology approach^[@R10]^ that integrates antibiotic delivery schedules and time-resolved microbiota data to mathematically model microbiota dynamics and infer which bacteria inhibit *C. difficile.* We included 24 allo-HSCT patients, 12 diagnosed with *C. difficile* infection and 12 that were *C. difficile* carriers without clinical infection ([Fig. 2d](#F10){ref-type="fig"}, [Extended Data Fig. 2](#F2){ref-type="fig"}). To facilitate comparisons across datasets, we clustered murine and human microbiota together to define OTUs (≥97% sequence similarity) that together accounted for a majority of both the human and mouse microbiota structure ([Extended Data Fig. 3a,b,c](#F3){ref-type="fig"}), and applied the modeling approach to the murine study in parallel. We compared the normalized interaction networks from the human ([Extended Data Fig. 3d](#F3){ref-type="fig"}) and the murine models ([Extended Data Fig. 3e](#F3){ref-type="fig"}) and identified bacteria displaying strong inhibition against *C. difficile*. Despite some differences across host species networks, the human model identified two *C. difficile*-inhibiting OTUs that were conserved in the murine model ([Fig. 2e, f](#F10){ref-type="fig"}), the strongest of which was *C. scindens*, corroborating our murine correlation-based analyses ([Fig. 2c](#F10){ref-type="fig"}).

To evaluate causality between intestinal bacteria identified in our analyses and infection resistance, we adoptively transferred resistance-associated bacteria. We cultured a representative consortium of four intestinal bacterial isolates with species-level 16S homology to OTUs associated with *C. difficile* inhibition in our mouse and human analyses ([Extended Data Fig. 4](#F4){ref-type="fig"}) and, following antibiotic administration, animals (n=10) were administered a suspension containing the 4-bacteria consortium or vehicle (PBS) prior to *C. difficile* infection. Additionally, since *C. scindens* had the strongest resistance associations in mice and humans ([Fig. 2c and e](#F10){ref-type="fig"}), we included this bacterium in the consortium and in a third arm alone. Adoptive transfer of the consortium or *C. scindens* alone ameliorated *C. difficile* infection ([Fig. 3a, b](#F11){ref-type="fig"}, [Extended Data Fig. 5a](#F5){ref-type="fig"}) as well as associated weight loss ([Fig. 3c](#F11){ref-type="fig"}, [Extended Data Fig. 5b](#F5){ref-type="fig"}) and mortality ([Fig. 3d](#F11){ref-type="fig"}) significantly compared to control. Transfer of the other three isolates individually, however, did not significantly enhance infection resistance ([Extended Data Fig. 5c](#F5){ref-type="fig"}). Engraftment of the transferred bacteria was confirmed ([Extended Data Fig. 5d](#F5){ref-type="fig"}) by 16S sequence homology with the input and the native intestinal bacteria from our initial analyses ([Fig. 2](#F10){ref-type="fig"}), thus fulfilling Koch's postulates (albeit between a microorganism and a beneficial health outcome). *C. scindens* abundance correlated significantly with infection resistance ([Fig. 3e](#F11){ref-type="fig"}), suggesting that improving bacterial engraftment efficiency may enhance the protective effects of the adoptive transfer. Importantly, bacteria transfer was precise and engraftment did not alter other aspects of microbiota structure compared to control, including density ([Extended Data Fig. 5e](#F5){ref-type="fig"}) and biodiversity ([Figure 3f](#F11){ref-type="fig"}).

We next interrogated the mechanism of *C. scindens*-mediated *C. difficile* inhibition. Some secondary bile acids can impair *C. difficile* growth *in vitro*^[@R11],[@R12]^, but the source and contribution of such metabolites to infection resistance *in vivo* remain unclear. Noting that *C. scindens* expresses enzymes crucial for secondary bile acid synthesis^[@R13]^ that are uncommon among intestinal bacteria^[@R14]^, we hypothesized that the *C. difficile*-protective effects of *C. scindens* may derive from this rare biosynthetic capacity. Analyses of antibiotic-exposed animals ([Figs. 1](#F9){ref-type="fig"}, [2](#F10){ref-type="fig"}) revealed that recovery of secondary bile acids and secondary bile acid biosynthesis gene family abundance (as predicted using PICRUSt^[@R15]^) correlated with *C. difficile* resistance ([Fig. 4a,b](#F12){ref-type="fig"}). Targeted microbiome analysis of the secondary bile acid biosynthesis gene family indicated that abundance of the bile acid-inducible (bai) operon genes correlated strongly with resistance to *C. difficile* infection ([Fig. 4c](#F12){ref-type="fig"}) but bile salt hydrolase (BSH)-encoding gene abundance did not, consistent with reports indicating that BSH-encoding genes are distributed broadly while an extremely small fraction of intestinal bacteria possess a complete secondary bile acid synthesis pathway^[@R14]^. PCR-based assay of *baiCD*, which encodes the 7α-hydroxysteroid dehydrogenase enzyme critical for secondary bile acid biosynthesis, revealed that animals that had recovered *C. difficile* resistance following antibiotic exposure harbored a *baiCD*+ microbiome, whereas susceptible animals did not ([Extended Data Fig. 6a](#F6){ref-type="fig"}).

Recipients of either the consortium or *C. scindens* harbored *baiCD+* microbiomes with restored secondary bile acid biosynthesis gene abundance (predicted by PICRUSt) ([Extended Data Fig. 6](#F6){ref-type="fig"}). Administration of either bacterial suspension also restored relative abundance of the secondary bile acids deoxycholate (DCA) ([Fig. 4d](#F12){ref-type="fig"}) and lithocholate (LCA) ([Extended Data Fig. 7a](#F7){ref-type="fig"}), both of which inhibit *C. difficile* in a dose-dependent fashion ([Extended Data Fig. 8a,b](#F8){ref-type="fig"}), but abundances of primary bile acids were not significantly altered ([Extended Data Fig. 7](#F7){ref-type="fig"}). Metagenomic inference indicated that consortia recipients harbored microbiomes with greater secondary bile acid biosynthesis gene abundance than *C. scindens* recipients ([Extended Data Fig. 6b](#F6){ref-type="fig"}), perhaps explaining their superior *C. difficile* resistance. However, intestinal DCA and LCA abundance was comparable in the two groups pre-infection challenge ([Fig. 4d](#F12){ref-type="fig"}, [Extended Data Fig. 7a](#F7){ref-type="fig"}), suggesting additional mechanisms enhanced colonization resistance in consortia recipients. Indeed, of the four transferred bacteria only *C. scindens* was *baiCD*+ ([Extended Data Fig. 6a](#F6){ref-type="fig"}). *C. scindens* engraftment also correlated strongly with DCA relative abundance and *baiCD* in recipients, reaching levels observed in antibiotic-naive animals ([Fig. 4e](#F12){ref-type="fig"}), indicating that precise transfer and efficient engraftment of this bacterium could restore physiological levels of secondary bile acid synthesis in antibiotic-exposed animals.

We evaluated bile acid-dependent microbiota-mediated *C. difficile* inhibition using an *ex vivo* model. Pre-incubation of intestinal content from antibiotic-naïve animals with cholestyramine, a bile acid sequestrant^[@R16]^, permitted *C. difficile* growth ([Extended Data Fig. 8c,d](#F8){ref-type="fig"}) comparable to intestinal content from antibiotic-exposed animals. Consistent with *in vivo* findings, introduction of *C. scindens* significantly inhibited *C. difficile* in the intestinal content from antibiotic-exposed animals. This effect was neutralized when intestinal content was pre-incubated with cholestyramine ([Fig. 4f](#F12){ref-type="fig"}), indicating that *C. scindens*-mediated *C. difficile* inhibition is dependent upon accessing and modifying endogenous bile salts and recapitulates a natural mechanism of microbiota-mediated infection resistance.

We show that a fraction of the intestinal microbiota as precise as a single bacterial species confers infection resistance by synthesizing *C. difficile*-inhibiting metabolites from host-derived bile salts. Our use of a human-derived *C. scindens* isolate to augment murine *C. difficile* inhibition underscores the conservation of this finding across species and suggests therapeutic and diagnostic applications. The genus *Clostridium* is phylogenetically complex^[@R17],[@R18]^, highlighting the value of integrating functional genomic and metabolomic interrogation with 16S rRNA profiling when evaluating probiotic candidates. Most bile acid 7-dehydroxylating bacteria are cluster XIVa *Clostridia* closely related to one another^[@R14],[@R19],[@R20]^ and resistance-associated OTUs we identified, suggesting that *bai* or 16S gene signatures may serve as specific, functionally meaningful biomarkers for infection resistance. The replenishment of secondary bile acids and/or biosynthesis-competent bacteria (such as *C. scindens*) may contribute to the therapeutic efficacy of FMT^[@R21]^. Attempts to directly manipulate intestinal bile acids should be performed with caution since some secondary bile acids have been linked to gastrointestinal cancers^[@R22]^. Other bacteria may augment resistance by enhancing 7-dehydroxylating *Clostridia* or through additional orthogonal mechanisms, such as competition for mucosal carbohydrates^[@R23]^, activation of host immune defenses^[@R24],[@R25]^, or production of antibacterial peptides^[@R26]^. Knowledge of such mechanisms and the ecological context of those microbes responsible will facilitate amplification of microbiota-mediated pathogen resistance in individuals at risk for infection.

Methods {#S1}
=======

Mouse husbandry {#S2}
---------------

All experiments were performed with C57BL/6J female mice, 6 to 8 weeks old, purchased from Jackson Laboratories and housed in sterile cages with irradiated food and acidified water. Mouse handling and weekly cage changes were performed by investigators wearing sterile gowns, masks, and gloves in a sterile biosafety hood. All animals were maintained in a specific-pathogen-free facility at Memorial Sloan-Kettering Cancer Center Animal Resource Center. Following co-housing for ≥2 weeks, animals (individuals or colonies, as indicated per experiment) were separately-housed and randomly assigned to experimental groups. For experiments involving *C. difficile* infection, mice were administered 1,000 *C. difficile* VPI 10463 spores in phosphate-buffered saline (PBS) by oral gavage. All animal experiments were performed at least twice unless otherwise noted. Experiments were performed in compliance with Memorial Sloan-Kettering Cancer Center institutional guidelines and approved by the institution's IACUC.

Murine *C. difficile* susceptibility time course experiments {#S3}
------------------------------------------------------------

Mice from three separately housed-colonies were kept in the same facility and administered clindamycin (administered by intraperitoneal injection, 200 μg q.d.), ampicillin (administered in drinking water, 0.1 g/L), or enrofloxacin (administered in drinking water, 0.4 g/L) for three days (days -2 through 0). At each time point (days 1, 6, 10, 14, and 21), one mouse from each of the three colonies was randomly selected to be single-housed, infected with *C. difficile*, and analyzed, yielding triplicate measurements per time point. Individual mice from each colony were isolated and challenged with *C. difficile* at intervals post-antibiotic cessation indicated, yielding triplicate biological replicates per group, per timepoint. Intestinal content (feces) was sampled prior to infection challenge for multiparallel 16S amplicon sequencing and microbiota structure analysis. *C. difficile* susceptibility was determined by selective culture and enumeration of colony-forming units (CFU) from intestinal content (cecum and colon) 24 hours post-challenge.

Murine *in vivo* adoptive transfer experiments {#S4}
----------------------------------------------

Six colonies of mice (n=30 total) were administered antibiotics as described previously^[@R27]^ and subsequently individually housed and assigned randomly to one of three groups. Two days following antibiotics, groups of individually-housed mice (n=10 per group) received either 1,000,000 CFU of a 4-bacteria suspension (containing equal numbers of *Clostridium scindens* (ATCC35704), *Barnesiella intestihominis* (isolated from murine feces in-house), Pseudoflavonifractor capillosus (ATCC29799), and *Blautia hansenii* (ATCC27752)), a suspension containing 1,000,000 *C. scindens*, or vehicle (PBS) by gavage. All bacteria were grown under anaerobic conditions in reduced Brain-Heart Infusion media supplemented with yeast extract and cysteine except for *B. intestihominis*, which was grown in liquid Wilkins-Chalgren media, and resuspended in anaerobic PBS prior to administration to animals. Adoptive transfers of the suspensions were performed once daily for two consecutive days prior to challenge with *C. difficile* VPI 10463 (1,000 spores in PBS). *C. difficile* bacteria and cytotoxin was quantified in fecal samples obtained from mice 24 hours after infection challenge. Animals were monitored for 21 days after infection challenge and weight loss was recorded.

Murine *ex vivo* adoptive transfer experiments {#S5}
----------------------------------------------

Three individually-housed mice were administered 200 μg of clindamycin by intraperitoneal injection and sacrificed 24 hours later. Intestinal content was harvested from the ilea of sacrificed animals, immediately transferred to an anaerobic chamber, and resuspended in anaerobic PBS. Fractions containing 100 mg of intestinal content from each mouse were distributed and received either *C. scindens* (100,000 CFU) or vehicle (anaerobic PBS). A third fraction was pre-treated with cholestyramine (1.5 mg) prior to receiving *C. scindens*. Following transfer, the each suspension was inoculated with vegetative *C. difficile* (200 CFU), incubated at 37°C for 60 hours, and *C. difficile* bacteria were quantified by overnight culture on selective media.

Quantitative *C. difficile* culture and toxin A and B {#S6}
-----------------------------------------------------

The quantities of *C. difficile* CFU and cytotoxin in the intestinal (cecal) contents of animals were determined as described previously^[@R2]^.

Enzymatic assay of secondary bile acid abundance {#S7}
------------------------------------------------

The relative abundances of primary and secondary bile acids in the intestinal content of sacrificed animals was quantified using an enzymatic assay as described previously^[@R28]^.

Sample collection and DNA extraction {#S8}
------------------------------------

Intestinal microbiota content samples were obtained, snap-frozen, stored, and DNA extracted as described previously^[@R29]^. Briefly, a frozen aliquot (≈100 mg) of each sample was suspended, while frozen, in a solution containing 500 μl of extraction buffer (200 mM Tris, pH 8.0/200 mM NaCl/20 mM EDTA), 200 μl of 20% SDS, 500 μl of phenol:chloroform:isoamyl alcohol (24:24:1), and 500 μl of 0.1-mm-diameter zirconia/silica beads (BioSpec Products). Microbial cells were lysed by mechanical disruption with a bead beater (BioSpec Products) for 2 min, after which two rounds of phenol:chloroform:isoamyl alcohol extraction were performed. DNA was precipitated with ethanol and resuspended in 50 μl of TE buffer with 100μg/ml RNase. The isolated DNA was subjected to additional purification with QIAamp mini spin columns (Qiagen). Specimen collection from patients and analysis of the biospecimen group was approved by the Memorial Sloan-Kettering Cancer Center Institutional Review Board. All subjects provided written consent for specimen collection and analysis.

Quantification 16S copy number density by quantitative RT-PCR {#S9}
-------------------------------------------------------------

DNA extracted from intestinal content samples (feces) was subjected to quantitative RT-PCR of 16S rRNA using 0.2 μM concentrations of the broad-range bacterial 16S primers 517F (5′-GCCAGCAGCCGCGGTAA-3′) and 798R (5′-AGGGTATCTAATCCT-3′) and the DyNAmo SYBR green qPCR kit (Finnzymes). Standard curves were generated by serial dilution of the PCR blunt vector (Invitrogen) containing one copy of the 16S rRNA gene derived from a member of the *Porphyromonadaceae* family. The cycling conditions were as follows: 95°C for 10 min, followed by 40 cycles of 95°C for 30 s, 52°C for 30 s, and 72°C for 1 min.

Quantification of *baiCD* by PCR {#S10}
--------------------------------

DNA extracted from intestinal content samples (feces) were subjected to PCR-based detection of the 7α-HSDH-encoding *baiCD* gene as described previously^[@R30]^.

16S rRNA gene amplification and multiparallel sequencing {#S11}
--------------------------------------------------------

Amplicons of the V4-V5 16S rRNA region were amplified and sequenced using an Illumina MiSeq platform for samples in the *in vivo* and *ex vivo* adoptive transfer experiments. For each sample, duplicate 50-μl PCR reactions were performed, each containing 50 ng of purified DNA, 0.2 mM dNTPs, 1.5 mM MgCl2, 1.25 U Platinum Taq DNA polymerase, 2.5 μl of 10X PCR buffer, and 0.2 μM of each primer designed to amplify the V4-V5: 563F (5′-nnnnnnnn-NNNNNNNNNNNN-AYTGGGYDTAAAGNG-3′) and 926R (5′-nnnnnnnn-NNNNNNNNNNNN-CCGTCAATTYHTTTRAGT-3′). A unique 12-base Golay barcode (Ns) precede the primers for sample identification^[@R31]^, and 1--8 additional nucleotides were placed in front of the barcode to offset the sequencing of the primers. Cycling conditions were 94°C for 3 minutes, followed by 27 cycles of 94°C for 50 seconds, 51°C for 30 seconds, and 72°C for 1 minute. 72°C for 5 min is used for the final elongation step. Replicate PCRs were pooled, and amplicons were purified using the Qiaquick PCR Purification Kit (Qiagen). PCR products were quantified and pooled at equimolar amounts before Illumina barcodes and adaptors were ligated on using the Illumina TruSeq Sample Preparation protocol. The completed library was sequenced on an Ilumina Miseq platform following the Illumina recommended procedures. Samples in the murine and human *C. difficile* susceptibility timecourse experiments were sequenced using the 454 FLX Titanium platform as described previously^[@R32]^. Sequences from allo-HSCT patients were obtained from a previously published study^[@R8]^.

Sequence analysis {#S12}
-----------------

Sequences were analyzed using the mothur^[@R33]^ (v.1.33.3) pipeline. Potentially chimeric sequences were removed using the UChime algorithm^[@R34]^. Sequences with distance-based similarity of 97% or greater were grouped into operational taxonomic units (OTUs) using the average neighbor algorithm and classified using the BLAST (megablast) algorithm and the Genbank 16S rRNA reference database, and OTU-based microbial diversity was estimated by calculating the Shannon diversity index. Sequences abundance profiles in each sample were used for downstream statistical and modeling analysis. A phylogenetic tree was inferred using Clearcut^[@R35]^, on the 16s rRNA sequence alignment generated by mothur, unweighted UniFrac^[@R7]^ was run using the resulting tree, and principal coordinate analysis (PCoA) was performed on the resulting matrix of distances between each pair of samples. PICRUSt (version 0.9.1)^[@R15]^ in combination with QIIME (version 1.6.0)^[@R36]^ was used to predict abundances of the secondary bile acid biosynthesis gene family (KEGG pathway ko00121) for a set of 83 samples. Maximum likelihood phylogenetic trees (Kimura model, bootstrap of 100 replicates) were constructed using the MEGA 6.06 package from representative sequences of intestinal bacteria as described^[@R37]^. Raw sequence data from metagenomic shotgun sequencing of six intestinal (ileal) microbiome samples were pre-processed to remove mouse-derived, duplicate, and low-quality reads as well as low-quality bases in accordance with Human Microbiome Project (HMP) protocols^[@R38]^ The remaining reads were mapped against a set of proteins associated the secondary bile acid biosynthesis pathway using RAPSearch 2.07^[@R39]^. For the subsequent analysis only hits with an e-value ≤ 0.1, a minimum alignment length of 30, and a minimum similarity of 50% were considered.

Quantification of secondary of bile acid species {#S13}
------------------------------------------------

Samples of murine intestinal content (feces, \~30 mg) were homogenized using a handheld homogenizer (Omni International) in 80% aqueous methanol and corrected to a final concentration of 0.5 mg / 10 μl. Samples were then sonicated using a Diagenode sonicator at high power, 6 × 30 sec cycles. 400 μl of this material was removed and 20 μl of internal standard added (25 μM d4-chenodeoxycholic acid in 55 % / 45 % methanol / water (v/v)). A further 1 ml methanol was added to the extract and samples were vortexed at 1,400rpm for 1 hr at 30°C (Thermomixer, Eppendorf). Remaining solid material was removed by centrifugation (21,000 × g for 10 min) and the supernatant transferred to a glass tube. A second extraction was performed using 1.5 ml methanol and combined supernatants were dried under a nitrogen gas stream. Finally samples were re-suspended in 300 μl 55 % / 45 % methanol / water (v/v), filtered through a 3 kDa molecular weight cut-off cartridge (Millipore) and transferred to a MS vial containing a reduced volume glass insert. Bile acids were separated using an Agilent 1290 HPLC and Cogent C18 column (2.1 mm × 150 mm, 2.2 μm; MicroSolv Technology Corporation). Mobile phase A: water + 0.05% formic acid; mobile phase B: acetone + 0.05% formic acid and flow rate: 0.35 ml/min. Injection volume was 5 ul and the LC gradient was from 25% B to 70% B in 25 min. Bile acids were detected using an Agilent 6550 Q-TOF mass spectrometer with JetStream source, operating in negative ionization mode and extended dynamic range. Acquisition was from m/z: 50 -- 1100 at 1 spectra/second; gas temperature: 275°C; drying gas 11 l/min; nebulizer: 30 psig; sheath gas: 325°C; sheath gas flow 10 l/min; VCap 4000 V; fragmentor 365 V and Oct 1 RF 750 V. Bile acids ([Extended Data Table 2](#T2){ref-type="table"}) were identified by their exact mass and confirmed by chromatographic alignment to authentic standards (purchased from Steraloids Inc or Sigma Aldrich). Abundances of the M-H and M+formate ions were then extracted and summed using ProFinder software (Agilent Technologies) and normalized to the internal standard abundance using Mass Profiler Professional software (Agilent Technologies).

Deoxycholate and lithochoate *C. difficile* inhibition assays {#S14}
-------------------------------------------------------------

Growth of *C. difficile* in Brain Heart Infusion (BHI) liquid media supplemented with yeast extract and cysteine, with added deoxycholate (DCA) (0.1%, 0.01%, 0.001%, final concentration, in water vehicle) or lithochoate (LCA) (0.01%, 0.001%, final concentration, in 100% ethanol vehicle), or vehicle alone was monitored by optical density (OD~600~) using a spectrophotometer.

Statistics {#S15}
----------

Statistical analyses were performed using the R (v. 3.0.2) and GraphPad Prism (v. 6.0c) software packages. The Mann-Whitney rank sum test (two-tailed) was used for comparisons of continuous variables between two groups with similar variances; the Kruskal-Wallis test with Dunn correction for multiple comparisons was used for comparisons of three groups or more (n≥5 samples per group) with similar variances. In all experiments involving group comparisons at least 6 animals were used per group; for these non-parametric tests, it was calculated that a sample size of 6 per group would be sufficient to detect an effect size of 2 with 90% power (alpha =0.05)^[@R40]^. Data were visualized using bar plots with center values representing the mean and error bars representing standard error of the mean, and box plots representing the median and interquartile range of the upper and lower quartiles and error bars showing the range. Spearman rank correlation tests (two-tailed) were used to find significant correlations between two continuous variables. Following statistical analyses with multiple comparisons we used the Benjamini-Hochberg method to control the false discovery rate. The log-rank test was used to find significant differences in the survival distributions among *C. difficile*-challenged groups of animals. When possible, investigators were blinded during group allocation and outcome assessment (16S and metagenomic shotgun sequence collection, extraction, quantification, and analysis; microbiota time-series inference modeling; quantification of bile species by enzymatic assay and HPLC-MS; enumeration of *C. difficile* in animal experiments).

Mouse microbiota time-series inference modeling {#S16}
-----------------------------------------------

In order to determine the network of bacterial--bacteria interactions and extract native resident bacteria with *C. difficile* inhibitory properties, we applied the Lotka-Volterra dynamics-based framework of Stein *et al*.^[@R10]^ to the mouse dataset. This inference framework consist of a regularized least-square regression of the observed data points and the known antibiotic signal against the difference of the log-transformed total abundances in time, i.e. $\frac{\Delta\ln x_{i}(t)}{\Delta t} = \left\lbrack {\ln\left( {x_{i}(t + \Delta t)} \right) - \ln\left( {x_{i}(t)} \right)} \right\rbrack/\Delta t\ \text{with~}i = 1\ldots N$, where *N* is the total number of considered OTUs. This results in coefficients characterizing growth, oriented interactions and susceptibilities of each OTU to the external perturbations. The method requires temporal profiles of total abundances of each of the 36 representatives OTUs, which were obtained by scaling their normalized abundance from the pyrosequencing run (fraction ranging from 0 to 1) by the total amount of bacteria DNA recovered from each gram of stool or intestinal content. The temporal profile of the *C. difficile* total abundance was obtained from the CFU counts recovered by plating the cecal content after mouse sacrifice. The last time differences Δln*x~i~* (*t*~inoc~), were calculated for each mouse as the difference between the total abundance in the intestinal content (feces) on the day after *C. difficile* inoculation, *t*~inoc~, (also day of mouse sacrifice) minus the total abundance in the content (fecss) prior to *C. difficile* infection or $\Delta\ln x_{i}(t_{inoc}) = \ln x_{i}^{colon}\left( {t_{inoc} + 1} \right) - \ln x_{i}^{feces}(t_{inoc})$. Similarly the differential profile for *C. difficile* was evaluated from log-difference in the scaled colony counts for the corresponding fecal and cecal samples. Antibiotic perturbations (ampicillin, clindamycin or enrofloxacin) were modeled as a discrete signal when administered at day -2 ([Fig. 1](#F9){ref-type="fig"}). The inference algorithm was run on a total of 240 samples and the global model was selected with a 3-fold cross-validation scheme on the 75 combined timecourses in order to ensure robustness to the introduction of unseen data^[@R10]^. In particular, the number of data points outnumbers the number of unknowns, i.e. the linear system to be solved is overdetermined, ensuring a sufficient number of constraints by the data for inferring the unknown coefficients.

Allo-HSCT patient microbiota time-series inference modeling {#S17}
-----------------------------------------------------------

In order to determine if commensal-*C. difficile* interactions observed in the mouse data were conserved also in humans we applied the same inference-modeling framework to data from 24 Allo-HSTC hospitalized patients. As above, for each of the 36 OTUs, we determined the log-differential in total abundance as the log-difference of the normalized abundance scaled by the corresponding total bacterial DNA per gram of stool at the next sampling event minus the total abundance at the current sampling time. Differential abundance in *C. difficile* was determined from the qPCR measurements of the *C. difficile* 16S rRNA gene per gram of feces. Similarly to above, we ran the algorithm on a total of 112 samples and the global model was selected applying a 3-fold cross-validation scheme on the 24 combined timecourses. This choice again yields an overdetermined linear system to be solved.

Extended Data {#S18}
=============

![Dynamics of intestinal microbiota structure and *C. difficile* susceptibility following antibiotic exposure\
Strategy for determining *C. difficile* susceptibility duration post-antibiotic exposure (n=3 separately-housed mouse colonies per antibiotic arm) and relating infection resistance to microbiota structure (**a**). Intestinal bacterial density of animals before and after antibiotic exposure (**b**). Results were representative of two independent experiments. Center values (mean), error bars (s.e.m.) (**b**). Relative abundance of bacterial OTUs (≥97% sequence identity, \>0.01% relative abundance) sorted by class (red) and corresponding *C. difficile* susceptibility (blue) among antibiotic-exposed mice (n=68) allowed to recover for variable time intervals prior to *C. difficile* infection challenge (**c**). Results were representative of two independent experiments. ND (not detectable).](nihms625849f1){#F1}

![Allo-HSCT patient timelines and *C. difficile* infection status transitions\
Transitions between *C. difficile* (*tcdB*-positive) colonization status in patients receiving allogeneic hematopoietic stem cell transplantation, as measured by *C. difficile* 16S rRNA abundance during the period of hospitalization (light gray bars). Timepoints when *C. difficile* colonization was determined to be positive (red diamonds) and negative (blue diamonds), and when *C. difficile* infection was clinically diagnosed (black dots) and metronidazole was administered (dark gray bars), are displayed relative to the time of transplant per patient.](nihms625849f2){#F2}

![Identification of bacteria conserved across human and murine intestinal microbiota predicted to inhibit *C. difficile*\
Identification of bacterial OTUs abundant in mice (n=68) and humans (n=24) (**a**) that account for a minority of OTU membership (**b**) but the majority of the structure of the intestinal microbiota of both host species following antibiotic exposure (**b**). Subnetworks of abundant OTUs predicted inhibit (blue) or positively associate with (red) *C. difficile* in murine (**c**) and human (**d**) intestinal microbiota.](nihms625849f3){#F3}

![Phylogenetic distribution of resistance-associated intestinal bacteria and isolates selected for adoptive transfer\
The maximum likelihood phylogenetic tree (Kimura model, bootstrap of 100 replicates) was constructed using the MEGA 6.06 package from representative sequences of intestinal bacteria associated with resistance to *C. difficile* infection (blue), including cultured representatives subsequently used in adoptive transfer experiments (bold). The tree was rooted using intestinal bacteria associated with susceptibility to infection (red) as an out-group.](nihms625849f4){#F4}

![Adoptive transfer and engraftment of four-bacteria consortium or *C. scindens* ameliorates intestinal *C. difficile* cytotoxin load and acute *C. difficile*-associated weight loss\
*C. difficile* toxin load in antibiotic-exposed animals receiving adoptive transfers 24 hours after *C. difficile* infection challenge (**a**). Animals weights 48 hours after infection challenge (**b**) and *C. difficile* CFU 24 hours after infection challenge (**c**). Engraftment of bacterial isolates in the intestinal microbiota of antibiotic-exposed animals two days following adoptive transfer of *B. intestihominis*, *P. capillosus*, *B. hansenii*, and/or *C. scindens* (**d**). Intestinal bacterial density (feces) from antibiotic-exposed mice administered suspensions containing 4 bacteria, *C. scindens*, or vehicle (PBS) as measured by quantitative RT-PCR of 16S rRNA genes (**e**). \*\*\*\*P\<0.0001, \*\*\*P\<0.001, \*\*P\<0.01, \*P\<0.05; Mann-Whitney (two-tailed) (**a**,**b,d,e**), Kruskal-Wallis with Dunn correction (**c**) (n=6--10 per group). Center values (mean), error bars (s.e.m.). Results were representative of at least two independent experiments. Numbers under group columns in (**a**) denote the number of mice with detectable engraftment of the given bacterium (out of 10 possible separately-housed animals per group) (**d**).](nihms625849f5){#F5}

![Adoptive transfer of consortia or *C. scindens* restores *baiCD* and secondary bile acid biosynthesis gene family abundance\
PCR-based detection of the 7α-HSDH-encoding *baiCD* gene in bacterial isolates, intestinal microbiomes (feces) of animals prior to antibiotic exposure, and intestinal microbiomes (feces) of animals that, following antibiotic exposure, remained *C. difficile*-susceptible or recovered resistance to infection spontaneously or following adoptive transfer of bacterial isolates (**a**). Reconstituted abundance of the secondary bile acid biosynthesis gene family, as predicted by PICRUSt, in antibiotic-exposed animals receiving adoptive transfers (n=10 per group) (**b**). \*\*\*P\<0.001, \*P\<0.05, ns (not significant); Mann-Whitney (two-tailed) (**b**). Center values (mean), error bars (s.e.m.).](nihms625849f6){#F6}

![Impacts of bacteria adoptive transfers on intestinal abundance of bile acids\
Intestinal abundance of the secondary bile acids lithochoate (LCA) (**a**), ursodeoxycholate (UDCA) (**b**), and primary bile acids (**c-f**) in mice following antibiotic exposure and adoptive transfer of bacteria indicated. \*\*\*\*P\<0.0001, \*P\<0.05, ns (not significant), Kruskal-Wallis test with Dunn's correction. Center values (mean), error bars (s.e.m.).](nihms625849f7){#F7}

![*C. difficile* growth inhibition by secondary bile acids and intestinal content from antibiotic-naive animals\
Addition of the secondary bile acids deoxycholate (DCA) (**a**) or lithochoate (LCA) (**b**) to culture media inhibits *C. difficile*. Bile acid-dependent inhibition of *C. difficile* enumerated by recovery of CFU after inoculation of vegetative *C. difficile* into cell-free (**c**) or whole (**d**) intestinal content harvested from C57BL/6J mice (n=5--6 per group), with or without pre-incubation with cholestyramine. \*\*P\<0.01, Mann-Whitney (two-tailed) (**c**,**d**).](nihms625849f8){#F8}

###### 

Characteristics of patients and transplant course.

  Parameter                                                                                      No. (% of patients)
  ---------------------------------------------------------------------------------------------- ---------------------
  Age (years)                                                                                    
   ≤29                                                                                           2/24 (8.3%)
   30--39                                                                                        5/24 (20.8%)
   40--49                                                                                        2/24 (8.3%)
   50--59                                                                                        6/24 (25.0%)
   ≥60                                                                                           9/24 (37.5%)
  Sex (female)                                                                                   10/24 (41.7%)
  Underlying Disease                                                                             
   Leukemia                                                                                      11/24 (45.8%)
   Lymphoma                                                                                      5/24 (20.8%)
   Multiple Myeloma                                                                              3/24 (12.5%)
   Myelodysplastic Syndrome                                                                      3/24 (12.5%)
   Other                                                                                         2/24 (8.3%)
  Conditioning Intensity                                                                         
   Nonmyeloablative                                                                              4/24 (16.7%)
   Reduced intensity                                                                             4/24 (16.7%)
   Myeloablative                                                                                 16/24 (66.7%)
  T-call depletion                                                                               13/24 (54.2%)
   Stem cell source (cord vs. other)                                                             5/24 (20.8%)
   Time to engraftment (≥l4d)[a](#TFN1){ref-type="table-fn"}^,^[b](#TFN2){ref-type="table-fn"}   5/24 (20.8%)
  Fever (T≥100.4)[b](#TFN2){ref-type="table-fn"}                                                 21/24 (87.5%)
  Vital Status: Dead[b](#TFN2){ref-type="table-fn"}                                              1/24 (4.2%)
  Total                                                                                          24/24 (100.0%)

Engraftment was defined as an absolute neutrophil count of \>500 cells/μL for 3 consecutive days.

Assessed during inpatient allogeneic hematopoietic stem cell transplantation hospitalization (from 15 days before transplant to 35 days after transplant).

###### 

Retention times for bile acids quantified by HPLC-MS.

  Compound   Molecular formula   Accurate mass   Retention time (min)   CAS number
  ---------- ------------------- --------------- ---------------------- ------------
  LCA        C24H40O3            376.29775       24.16                  434--13--9
  UDCA       C24H40O4            392.29266       16.59                  128--13--2
  DCA        C24H40O4            392.29266       20.42                  83--44--3
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![Different antibiotics induce distinct changes to *C. difficile* infection resistance and intestinal microbiota composition\
Susceptibility to *C. difficile* infection following clindamycin (**a**), ampicillin (**b**), or enrofloxacin (**c**). Correlation of *C. difficile* CFU and toxin in cecal content following infection (**d**). Intestinal microbiota composition at timepoints indicated (**e**,**f**,**g**). Each stacked bar represents the mean microbiota composition of three separately-housed animals. \*\*\*\*P\<0.0001. Center values (mean), error bars (s.e.m.) (**a**, **b**, **c**).](nihms625849f9){#F9}

![Native intestinal bacterial species conserved across murine and human microbiota are predicted to inhibit *C. difficile* infection\
Intestinal microbiota alpha diversity (**a**) and Beta diversity (weighted UniFrac distances) (**b**) of antibiotic-naïve (n=15) and antibiotic-exposed animals susceptible (n=21) or resistant (n=47) to *C. difficile* infection. Correlation of individual bacterial OTUs with susceptibility to *C. difficile* infection (**c**). Colonization (*C. difficile*-negative to -positive) and clearance (*C. difficile*-positive to --negative) events among *C. difficile*-diagnosed and carrier patients included in microbiota time-series inference modeling (**d**). Bacterial species with strong *C. difficile* interactions in human and murine microbiota models (**e**) that exist in a conserved subnetwork predicted to inhibit (blue) or positively associate (red) with *C. difficile* (**f**). \*\*\*P\<0.001. In (**c**), P\<0.0005 ("any biodiversity", n=68) or P\<0.05 ("Low biodiversity", Shannon≤1 (n=16 animals). Center values (mean), error bars (s.e.m.).](nihms625849f10){#F10}

![Adoptive transfer of resistance-associated intestinal bacteria following antibiotic exposure increases resistance to *C. difficile* infection\
Intestinal burden of *C. difficile* CFU (**a**) and toxin (**b**) 24 hours after *C. difficile* infection of antibiotic-exposed animals receiving adoptive transfers. Weight loss (**c**) and mortality (**d**) of animals post-infection. Correlation of adoptively-transferred bacteria engraftment with *C. difficile* susceptibility, (**e**) and microbiota biodiversity (**f**) pre-infection. \*\*\*\*P\<0.0001, \*\*P\<0.01, \*P\<0.05, ns (not significant). Mean (**f**)), error bars (range (**a**), s.e.m. (**f**)).](nihms625849f11){#F11}

![*C. scindens*-mediated *C. difficile* inhibition is associated with secondary bile acid synthesis and dependent on bile endogenous to intestinal content\
Relative abundance of secondary bile species (**a**) and biosynthesis gene abundance predicted by PICRUSt (**b**) in intestinal content from antibiotic-exposed *C. difficile* susceptible (n=21), resistant (n=47), and pre-antibiotic (n=15) animals. Correlation of *C. difficile* susceptibility with secondary bile acid biosynthesis gene family abundance in intestinal content (n=6) quantified using shotgun sequencing (**c**). Intestinal abundance of deoxycholic acid (DCA) following adoptive transfer of bacteria (n=10 per group) (**d**). Correlation of *C. scindens* engraftment with DCA abundance and *baiCD* status in intestinal content of antibiotic-exposed, adoptively transferred animals (n=30) (**e**). Bile acid-dependent *C. scindens*-mediated inhibition of *C. difficile* quantified *ex vivo* (n=6 per group) (**f**). \*\*\*\*P\<0.0001, \*\*\*P\<0.001, \*\*P\<0.01, \*P\<0.05. Gylceroltransferase F51, endogenous reference gene (**c**). Shaded region around mean 'pre-antibiotic (abx)' DCA abundance (s.d.) (**e**).](nihms625849f12){#F12}
